Hidden Prediabetes at Work — What Screening Reveals | 2026

There's a number that benefits administrators across the country keep encountering when they analyze their annual biometric screening data, and it tends to generate a particular kind of uncomfortable silence in the room. Not the silence of a shocking discovery — it's too consistent across too many organizations for shock to be the right word anymore. More like the silence of a pattern that's been there all along, hiding in plain sight behind a metric that most wellness programs weren't quite measuring precisely enough to see it.

That number is the proportion of employees whose glucose markers fall in the prediabetes range — fasting glucose between 100 and 125 mg/dL, or A1C between 5.7% and 6.4% — who have no idea that's where they sit. The CDC has estimated that approximately 96 million American adults have prediabetes, and that roughly 80% of them are unaware of it. In a workforce context, those percentages translate directly into a substantial and largely invisible population of employees whose blood sugar patterns are already drifting in a direction that, without any intervention in lifestyle or awareness, research consistently associates with eventual progression toward type 2 diabetes and the cluster of cardiometabolic complications that follow in its wake.

This article explores what population-level biometric screening data has revealed about the prevalence and distribution of prediabetes-range glucose patterns in the working-age American population, how aggregate workforce data is being used in wellness planning conversations, and why the question of early glucose awareness has become one of the more pressing items on the corporate health benefits agenda in 2026.

What Population-Level Screening Reveals About Glucose Patterns

When a large employer conducts annual biometric screenings across their workforce — drawing fasting glucose and, increasingly, A1C from thousands of employees in a single program cycle — the resulting dataset is a population health snapshot of uncommon granularity. It's not a clinical database or a research cohort. It's a real-world cross-section of working-age American adults, most of whom haven't been screened recently outside their annual physical, many of whom haven't had an A1C drawn at all if their fasting glucose was normal enough to avoid the prompt.

What these datasets reveal, when analyzed in aggregate, is a glucose distribution that tends to follow a familiar and somewhat sobering shape. A meaningful proportion of the workforce sits comfortably in the normal range — fasting glucose below 100, A1C below 5.7%. A smaller but clinically significant proportion has crossed into diagnosed type 2 diabetes territory, either known or newly flagged by the screening. And in the middle — that grey zone between unambiguously normal and clinically diagnosable — sits a segment of the workforce that is consistently larger than most organizations expect when they first look at the data.

The prediabetes-range population is the one that workforce health researchers find most analytically interesting, because it's the segment where the metabolic story is still unwritten. These are individuals whose pancreatic beta cells are working harder than they should to maintain glucose within the normal clinical range — compensating for early insulin resistance by secreting more insulin, more frequently, with gradually diminishing efficiency. The fasting glucose number may look near-normal. The A1C may hover in the high-5s. From the outside, from the perspective of a standard annual physical, everything appears fine. But the machinery is straining. Like a car engine that still starts in the morning but takes a few extra turns of the key and runs rougher than it did three years ago — technically functional, but not running the way it's supposed to.

The A1C Advantage — Why Three Months Tells a Different Story

The single most consequential addition that progressive employer screening programs have made to their standard biometric protocols is the addition of A1C alongside fasting glucose. It sounds like a minor technical detail. It's actually a meaningfully different kind of information. Fasting glucose measures glucose at one specific moment — after an overnight fast, under controlled pre-draw conditions, on a single morning that may or may not be representative of the individual's typical glucose patterns. A1C measures the average glucose concentration over approximately the preceding three months, derived from the proportion of hemoglobin molecules that have been glycated — chemically bonded with glucose — during that period.

The difference in information content between these two measurements is the difference between a photograph and a time-lapse video. A fasting glucose of 98 mg/dL is a photograph taken on a Tuesday morning. An A1C of 5.9% is a summary of the full three-month metabolic film — capturing the post-meal glucose excursions, the overnight patterns, the stress-related spikes, the days when dietary patterns shifted and blood sugar ran higher for a stretch. Two employees with nearly identical fasting glucose values can have A1C values that diverge meaningfully, because their post-meal glucose patterns — invisible to the fasting draw — are telling different stories about how their bodies are handling carbohydrate loads throughout the day.

In population-level screening data, the addition of A1C consistently identifies a segment of the workforce that fasting glucose alone misses: individuals whose fasting glucose falls in the normal or near-normal range but whose A1C is already in the prediabetes zone, reflecting elevated average glucose driven by post-meal patterns that fasting measurement doesn't capture. These are employees who would have been classified as metabolically healthy by a fasting-only protocol, but whose three-month glucose average is already telling a different story. They're the ones the cluttered basement of standard screening tends to leave undiscovered — the metabolic drift accumulating in the back corner where nobody's been looking.

The Prevalence of Undetected Prediabetes in Working Adults

The unique conceptual framework this article introduces for the cluster is the Subthreshold Prevalence Paradox — the observation that prediabetes is simultaneously one of the most prevalent metabolic conditions in the American working-age population and one of the most systematically underdetected, not because the tools to detect it are unavailable or expensive, but because the standard screening protocols that most employers and annual physicals rely on are calibrated to catch clinical diagnoses rather than the upstream metabolic drift that precedes them.

The paradox operates like this: prediabetes-range glucose patterns affect somewhere between one-third and one-fourth of all American adults, depending on which diagnostic criteria are applied and which population is studied. Among adults over forty — the demographic that constitutes the majority of most established workforces — the prevalence is higher. Among adults with sedentary occupational profiles, obesity, or family history of type 2 diabetes, higher still. And yet, because prediabetes produces no symptoms that most people would identify as connected to blood sugar — the fatigue, the brain fog, the difficulty losing weight, the insistent afternoon hunger are all easily attributed to stress, sleep, age, or lifestyle — the vast majority of affected individuals move through their days without any awareness of where their metabolic markers actually sit.

Research examining screening data from large employer wellness programs has found that the proportion of newly identified prediabetes-range employees in any given screening cycle — individuals who had no prior diagnosis and no awareness of their glucose status — tends to be substantially higher than most organizations expect from their workforce demographics alone. The working-age population isn't self-selecting toward metabolic health. It's self-selecting toward the professions and lifestyles that research consistently links to sedentary behavior, chronic stress, sleep disruption, and dietary patterns that are associated with worsening insulin sensitivity over time. The prediabetes prevalence numbers that sound surprising on a population-health slide are less surprising when viewed through the lens of what a typical American desk-job workday actually does to the metabolic system over ten or twenty years.

How Employers Use Aggregate Lab Data for Wellness Planning

The translation of individual biometric screening data into aggregate population health intelligence is where the corporate wellness industry has developed some of its most practically valuable analytical capabilities — and also where some of its most significant limitations are most visible.

In organizations with mature benefits analytics functions, annual biometric data is analyzed not as a collection of individual lab results but as a population health dataset that can reveal trends, distributions, and year-over-year shifts in the aggregate metabolic profile of the workforce. The questions a sophisticated benefits team asks of this data aren't about individual employees — privacy frameworks and legal constraints appropriately limit that kind of individualized use — but about the population: What proportion of our workforce is in each glucose category, and how has that distribution shifted over three years? Are average triglyceride levels rising across the population? Is the proportion with A1C in the prediabetes range growing, stable, or declining? Is the metabolic risk distribution of the workforce moving toward greater risk or away from it?

These population-level questions matter enormously for financial planning. Chronic metabolic conditions are among the most expensive claims categories in any employer health plan, and their costs are driven not by acute events but by the cumulative utilization of ongoing disease management, specialist care, pharmacy, and eventually the downstream complications — neuropathy, nephropathy, cardiovascular events — that accrue over years of insufficiently managed metabolic disease. A workforce whose aggregate prediabetes prevalence is increasing is a workforce whose future type 2 diabetes incidence is likely to increase in parallel, with a claims cost trajectory that will follow. Understanding where the population sits today is, in the actuarial framing, understanding what the plan is likely to cost in five and ten years.

• Year-over-year fasting glucose distribution shifts — tracking whether the workforce population is moving toward or away from prediabetes-range concentrations
• A1C category distribution — identifying the proportion with values in the normal, prediabetes, and diabetes ranges, and tracking changes over time
• Screening participation rates by department or job category — ensuring the biometric data represents the full workforce rather than only the health-conscious volunteers
• Triglyceride and HDL trends — lipid markers that often shift in parallel with glucose metabolism changes and provide additional metabolic risk signal
• Cross-referencing claims data with biometric trends — validating whether populations with adverse biometric profiles generate higher utilization in cardiometabolic claims categories

Why Early Awareness Matters in Workforce Health Conversations

The public health argument for early glucose awareness — catching prediabetes-range patterns before they progress — rests on a well-established body of research showing that the trajectory from prediabetes to type 2 diabetes is not inevitable, and that the lifestyle factors most strongly associated with favorable trajectory changes are most effective when deployed early, when the metabolic system retains enough flexibility to respond to them. By the time A1C crosses the 6.5% threshold and a formal diabetes diagnosis is made, the beta cell function responsible for insulin production has often been compromised to a degree that significantly complicates the response.

In the workforce context, the early awareness argument takes on an additional economic dimension. The cost of identifying and engaging a prediabetes-range employee through a structured wellness program is substantially lower than the cost of managing that same employee's type 2 diabetes and its complications over the following decade. This cost-benefit arithmetic has been documented in multiple employer wellness program analyses and in the economic modeling underlying the CDC's prediabetes trajectories, which was specifically designed to deploy the lifestyle intervention findings of the Diabetes Prevention Program research trial at scale in real-world community and workplace settings.

The challenge, as with so many population health interventions, is engagement. Annual biometric screening identifies the prediabetes-range population. Getting a meaningful proportion of that population to act on that information — to move from awareness to the sustained behavioral changes that population research links to favorable metabolic trajectories — is considerably harder. Oddly enough, this is where the framing of the conversation matters as much as the data itself. Employees who receive their biometric results as a scare — "you're headed toward diabetes" — tend to disengage. Those who receive them as a piece of interesting self-knowledge — "here's where your glucose pattern sits, and here's what that means for your energy and long-term metabolic picture" — are more likely to stay curious and engaged with the information.

Frequently Asked Questions

What does employer biometric screening reveal about prediabetes prevalence?

Population-level biometric screening data from large employer wellness programs consistently reveals that a substantial proportion of working-age adults have glucose markers in the prediabetes range — fasting glucose between 100 and 125 mg/dL or A1C between 5.7% and 6.4% — without any prior awareness of their glucose status. The CDC estimates that approximately 80% of the 96 million American adults with prediabetes are unaware of their condition.

Why is A1C more informative than fasting glucose alone in workforce screening?

A1C reflects average blood glucose over approximately three months, capturing post-meal glucose patterns, overnight behavior, and intraday variability that fasting glucose cannot detect. In workforce screening programs, adding A1C to fasting glucose consistently identifies a prediabetes-range population that fasting-only protocols miss — individuals whose three-month glucose average reveals metabolic drift not visible in a single fasting measurement.

What is the Subthreshold Prevalence Paradox?

This framework describes the observation that prediabetes is simultaneously one of the most prevalent metabolic conditions in the working-age US population and one of the most systematically underdetected — not because detection tools are unavailable, but because standard screening protocols are calibrated to identify clinical diagnoses rather than the upstream metabolic drift that precedes them, leaving a large proportion of the at-risk population unaware of their glucose status.

How do employers use aggregate biometric data in wellness planning?

Organizations with mature benefits analytics functions analyze aggregate biometric data to track population-level metabolic trends over time — including the distribution of employees across glucose categories, year-over-year shifts in A1C and triglyceride averages, and cross-referencing of biometric risk profiles with claims utilization data — without individualizing the analysis in ways that would raise privacy concerns.

Why does early prediabetes detection matter for workforce health economics?

Research and actuarial modeling consistently find that the cost of engaging prediabetes-range employees through structured wellness programs is substantially lower than the downstream cost of managing type 2 diabetes and its complications. Because metabolic conditions develop over years before clinical diagnosis, population health programs that identify and address glucose drift early have the widest window for favorable trajectory impact and the most favorable cost-benefit profiles.

What makes prediabetes difficult to detect without screening?

Prediabetes produces no symptoms that most people would specifically associate with blood sugar — the fatigue, cognitive fog, hunger, and difficulty with weight management that may accompany early insulin resistance are typically attributed to stress, poor sleep, aging, or lifestyle factors. Without a direct glucose measurement, the condition is essentially invisible — which is why population-level biometric screening remains the primary mechanism for identifying the prediabetes-range workforce population.

The aggregate picture that employer screening data has assembled over the past decade is, at minimum, a useful corrective to the assumption that "healthy enough to work" translates to "metabolically well." For a substantial and systematically undercounted proportion of the American workforce, the glucose story is already in motion — trending in a direction that hasn't yet produced a clinical label but has almost certainly already begun shaping their energy, their focus, the way their afternoons feel, and the trajectory of the health costs that will follow them, and their employers, into the decade ahead.